...Inc. appointed Mark Iwicki as chairman. Iwicki, who currently serves as chairman and CEO of Kala Pharmaceuticals Inc....

...alfa (AMG 592).FDA approves Kala’s dry eye drug; shares tumbleFDA approved Eysuvis loteprednol 0.25% from Kala Pharmaceuticals Inc....

...a very selective buying opportunity. For instance, Linimeier said his firm added a position in Kala Pharmaceuticals Inc....

...Officer and acting CFO Edward Imbrogno will become the permanent CFO. Kala raises $126M follow-on Kala Pharmaceuticals Inc....
...that they will utilize the extension and summarizing why it is needed. BioCentury Staff InnoCare Pharma Ltd. BioSight Ltd. Kala Pharmaceuticals Inc. PDL...

...of $40.78 on Tuesday, before the takeout was announced. Setback for Kala’s dry eye treatment Kala Pharmaceuticals Inc....
...etabonate mucosal penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala Pharmaceuticals Inc. miRagen...

...assessed to be at imminent risk for suicide Phase III data; submit sNDA 2H19; 4Q19 Kala Pharmaceuticals Inc....

...daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA) PDUFA date 3/20/19 Kala Pharmaceuticals Inc....

...FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial...
...up 17% to $5.02. Allison Johnson Edsivo, celiprolol (ACER-002) Inveltys, LE-MPP, Loteprednol etabonate mucosal penetrating particle (KPI-121) Acer Therapeutics Inc. Kala Pharmaceuticals Inc. Adrenergic...

...sleepiness in patients with obstructive sleep apnea and narcolepsy PDUFA date; submit MAA 12/20/18; YE18 Kala Pharmaceuticals Inc....

...HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy Kala Pharmaceuticals Inc....